Exploring the Therapeutic Potential of Metformin and Vitamin D 3 Combination in the Management of Diabetes Mellitus
Authors:
- Md. Ferdaus AzamMAMd. Ferdaus Azam
- Md. Abu Bakar Siddique JamiMJMd. Abu Bakar Siddique Jami
- Nafis Yamin SuprioNSNafis Yamin Suprio
- Md. Ismail KabirMKMd. Ismail Kabir
- Sabrina Tasnim OishiSOSabrina Tasnim Oishi
- Jannatul Ferdous EkraJEJannatul Ferdous Ekra
- Nusrat IslamNINusrat Islam
- Samia ZamanSZSamia Zaman
- Md. Mofazzal HossainMHMd. Mofazzal Hossain
- Md. Al AminMAMd. Al Amin
Open Access
- 1 November 2026
- journal article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Abstract
Background: Diabetes mellitus is a chronic metabolic disorder characterised by hyperglycaemia, dyslipidaemia, hepatic dysfunction, and loss of pancreatic β‐cells. Vitamin D 3 (D 3 ) may influence glucose and lipid metabolism and has been investigated for its potential complementary effects when administered with metformin (MT). In the present study, the anti‐diabetic activity of D 3 alone and when combined with MT was evaluated in Streptozotocin (STZ) induced diabetic mice. Methods: Swiss albino mice were made diabetic using STZ (45 mg/kg) injected intraperitoneally for 3 days. Diabetic mice were treated with MT (250 mg/kg), D 3 (100 μg/kg), or MT + D 3 for 21 days. The fasting blood glucose, serum lipid profile, body weight, alanine aminotransferase (ALT), and pancreatic histopathology were assessed. The data were analysed by ANOVA and Tukey's post hoc test, and a p ‐value < 0.05 was considered statistically significant. Results: The diabetic STZ mice showed sustained hyperglycaemia, weight loss, dyslipidaemia, increased ALT activity and degeneration of the islets of Langerhans. MT and D 3 treatments were associated with improvements in glycaemic control, and the combination treatment showed the greatest effect. Combined treatment was found to lower the level of total cholesterol (93.06 ± 2.89 mg/dL), LDL (28.66 mg/dL), triglycerides (120.33 ± 2.10 mg/dL) and ALT activity (52.60 ± 3.05 IU/L) and increase HDL (40.33 ± 2.10 mg/dL) when compared with diabetic controls. Moreover, the MT + D 3 group exhibited significant changes in the total cholesterol/HDL and LDL/HDL ratio and preserved the histoarchitecture of the pancreas. Conclusion: Metformin and vitamin D 3 , administered individually or in combination, were associated with improvements in several diabetes‐related metabolic parameters. The combination group showed greater observed metabolic outcomes than either treatment alone in STZ‐induced diabetic mice. Further adequately powered preclinical and clinical studies are required to determine the therapeutic relevance of this combination.Keywords
This publication has 27 references indexed in Scilit:
- Dyslipidemia in diabetesIndian Heart Journal, 2023
- Lipid-lowering in diabetes: An updateAtherosclerosis, 2023
- Neuromodulatory effect of the combination of metformin and vitamin D3 triggered by purinergic signaling in type 1 diabetes induced-ratsMolecular and Cellular Endocrinology, 2023
- The glucose tolerance test in mice: Sex, drugs and protocolDiabetes, Obesity and Metabolism, 2022
- Antidiabetic effects of the ethanolic extract of Allium saralicum R.M. Fritsch on streptozotocin‐induced diabetes in a mice modelFood Science & Nutrition, 2021
- Streptozotocin‐Induced Diabetic Models in Mice and RatsCurrent Protocols, 2021
- Biomedical effects of Laurus nobilis L. leaf extract on vital organs in streptozotocin-induced diabetic rats: Experimental researchAnnals of Medicine & Surgery, 2021
- Structural dependence of antidiabetic effect of steviol glycosides and their metabolites on streptozotocin‐induced diabetic miceJournal of the Science of Food and Agriculture, 2020
- 1,25-Dihydroxyvitamin D3 enhances glucose-stimulated insulin secretion in mouse and human islets: a role for transcriptional regulation of voltage-gated calcium channels by the vitamin D receptorThe Journal of Steroid Biochemistry and Molecular Biology, 2019
- Metformin prevents glucotoxicity by alleviating oxidative and ER stress–induced CD36 expression in pancreatic beta cellsJournal of Diabetes and its Complications, 2017